2022 MASCC/ISOO Annual Meeting on Supportive Care in Cancer
Double-Blind, Randomized, Placebo-Controlled Multi-Center Phase 3 BUM-5 Study Followed by Open-Label Phase on the Efficacy and Tolerability of Budesonide in Patients With Resistant Oral Chronic GVHD
Comments 0
Login to view comments.
Click here to Login
